Skip to content
Screener

Alkermes ALKS Stock-Based Comp

Stock-Based Comp at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$135M-1.5%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$74.5M+10.0%
AbbVie logo
AbbVieABBV
$444M+8.3%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$23.44M+0.6%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
$9M+50.0%
LBR
LB Pharmaceuticals IncLBRX
$2.57M+305%

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.32B+89.9%
Enterprise value$9.38B+139%
P/E125.9×+113×
P/S+2.1×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
Line itemSix Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Adjustments to reconcile net income to cash flows from operating activities:
Depreciation and amortization49,70515,239
Amortization of inventory step-up43,728
Share-based compensation expense67,46947,776
Change in fair value of contingent consideration26,414
Deferred income taxes317(900)
Other non-cash charges5,5773,245
Changes in assets and liabilities:

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's stock-based comp?
Alkermes (ALKS) reported stock-based comp of $31.14M in Q2 2026.
How has Alkermes's stock-based comp changed year-over-year?
Alkermes's stock-based comp increased by 24.7% year-over-year, from $24.97M to $31.14M.
What is the long-term trend for Alkermes's stock-based comp?
Over 4 years (2021 to 2025), Alkermes's stock-based comp has grown at a 3.0% compound annual growth rate (CAGR), from $87.62M to $98.72M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ask your AI about Alkermes's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude